Ascletis Pharma Inc. (ASCLF.PK) Monday announced initiation of two Phase 1 studies evaluating ASC30 as both once-monthly subcutaneous injection and once-daily oral tablet for the treatment of obesity.
The Company expects topline data from both the studies in the first quarter of 2025.
Ascletis said that ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once-monthly subcutaneously and once-daily orally to treat obesity.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.